Profound Medical Corp. has increased the size of its private placement to accommodate a long-term existing investor, raising up to US$6.45 million through the issuance of 921,428 common shares at US$7.00 per share. The Offering is expected to close on or before December 30, 2025. The net proceeds will be used for sales and marketing, research and development, and general corporate purposes. No securities will be sold to U.S. purchasers. Profound is a medical device company developing AI-powered, MRI-guided therapies for tissue ablation, including the TULSA-PRO system for prostate treatment and Sonalleve for various conditions.

Read more at GlobeNewswire: Profound Medical Corp. Announces Upsize of Private